GO:0001975 response to amphetamine: Neuropharmacology, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001975 response to amphetamine describes any process that changes a cell or organism's state or activity following amphetamine exposure, including movement, secretion, enzyme production, and gene expression [QuickGO definition].
• Amphetamines are a group of compounds related to alpha-methylphenethylamine, and their effects are studied in both clinical and preclinical settings [QuickGO definition].
• Genetic variation in the norepinephrine transporter gene (SLC6A2) modulates acute subjective and cardiovascular responses to d-amphetamine in healthy volunteers.
• Individual differences in impulsivity and inattention predict subjective responses to d-amphetamine, linking cognitive traits to drug response.
• Amphetamine alters neural responses to rewarding stimuli such as sucrose in healthy women, as shown by functional neuroimaging.
• Childhood adversity and ethnicity influence acute subjective effects of stimulants, highlighting the importance of gene-environment interactions in response to amphetamine [7,8].
Description
The Gene Ontology (GO) term GO:0001975, response to amphetamine, defines any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amphetamine stimulus [QuickGO definition]. Amphetamines consist of a group of compounds related to alpha-methylphenethylamine, and they are widely used both clinically and as pharmacological tools [QuickGO definition]. Understanding this response is critical for researchers studying neuropsychiatric disorders, substance use, and individual variability in drug effects. Clinical studies have shown that acute subjective and cardiovascular responses to d-amphetamine vary among individuals and are influenced by genetic and environmental factors [2,3,7,8]. For example, polymorphisms in the norepinephrine transporter gene (SLC6A2) modulate the acute response to d-amphetamine in healthy volunteers. Additionally, impulsivity and inattention traits are associated with subjective responses to d-amphetamine, suggesting that cognitive phenotypes may predict drug sensitivity. Preclinical and clinical research has also demonstrated that amphetamine alters neural responses to rewarding stimuli, such as sucrose, in healthy women. These findings underscore the importance of characterizing the molecular and physiological pathways that mediate response to amphetamine. This article synthesizes current knowledge on the genes, mechanisms, and research methods relevant to GO:0001975, providing a resource for biomedical researchers and AI-driven knowledge retrieval.
response to amphetamine At A Glance
| GO ID | GO:0001975 |
|---|---|
| GO term | response to amphetamine |
| Ontology | biological_process |
| Synonym | none |
| Definition | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amphetamine stimulus. Amphetamines consist of a group of compounds related to alpha-methylphenethylamine. |
| Major function | Mediates physiological and behavioral responses to amphetamine exposure |
| Related genes | SLC6A2, DRD2, DRD4, COMT, and others involved in monoamine signaling |
| Research relevance | Implicated in ADHD pharmacotherapy, substance use disorders, and individual variability in drug response |
What Is GO:0001975?
GO:0001975 response to amphetamine is a biological process term that encompasses any change in a cell or organism's state or activity following exposure to amphetamine. This includes alterations in movement, secretion, enzyme production, gene expression, and other physiological responses. Amphetamines are a class of compounds related to alpha-methylphenethylamine, and the term covers responses to this group as a whole [QuickGO definition].
Why Is response to amphetamine Important in Cell Biology?
Understanding GO:0001975 is essential because amphetamines are clinically used to treat attention deficit hyperactivity disorder (ADHD) and are also drugs of abuse. The response to amphetamine varies widely among individuals due to genetic, environmental, and cognitive factors [2,3,7,8]. Elucidating the mechanisms underlying this response can inform personalized medicine approaches, predict therapeutic outcomes, and identify risk factors for adverse effects or substance use disorders. Moreover, amphetamine serves as a pharmacological probe to study monoamine neurotransmission and reward circuitry.
• Amphetamines are first-line pharmacotherapy for ADHD, and response variability affects treatment efficacy.
• Genetic polymorphisms in SLC6A2 influence acute subjective and cardiovascular responses to d-amphetamine.
• Impulsivity and inattention traits predict subjective responses to d-amphetamine, linking cognition to drug effects.
• Amphetamine alters neural responses to rewarding stimuli, relevant to addiction and reward processing.
• Childhood adversity and ethnicity contribute to individual differences in stimulant response [7,8].
• Response to amphetamine is a model for studying gene-environment interactions in neuropsychopharmacology.
• Preclinical studies of repeated amphetamine administration reveal metabolic and behavioral adaptations.
• Amphetamine response in borderline patients differs from controls, suggesting clinical heterogeneity.
• Understanding amphetamine response aids in developing safer and more effective stimulant medications.
• GO:0001975 provides a standardized framework for annotating genes and pathways involved in amphetamine effects.
What Happens During response to amphetamine?
Acute Subjective and Cardiovascular Effects
In simple terms: When a person takes amphetamine, they may feel more alert or euphoric, and their heart rate and blood pressure can change.
Acute administration of d-amphetamine produces subjective effects such as euphoria, increased energy, and alertness, as well as cardiovascular changes including increased heart rate and blood pressure. These responses are measured in controlled human studies using standardized questionnaires and physiological monitoring [2,3,7,8]. For example, Weafer et al. (2013) found that impulsivity and inattention are associated with subjective responses to d-amphetamine. Dlugos et al. (2007) demonstrated that variation in the norepinephrine transporter gene (SLC6A2) modulates acute subjective and cardiovascular responses to d-amphetamine. Carlyle et al. (2024) showed that childhood adversity impacts acute subjective effects of stimulants, including amphetamine. Pang et al. (2016) reported that Asians compared to Whites show increased response to d-amphetamine on select subjective and cardiovascular measures.
Neural and Reward Circuitry Responses
In simple terms: Amphetamine changes how the brain responds to rewards, such as sweet tastes.
Amphetamine alters neural responses to rewarding stimuli. Melrose et al. (2016) used functional magnetic resonance imaging (fMRI) to show that amphetamine alters neural response to sucrose in healthy women, indicating effects on reward processing. This suggests that amphetamine modulates brain circuits involved in reward and motivation, which may be relevant to its addictive potential and therapeutic effects.
Behavioral and Metabolic Adaptations to Repeated Exposure
In simple terms: With repeated use, the body and brain may adapt, leading to changes in behavior and metabolism.
Repeated administration of amphetamine can lead to behavioral sensitization or tolerance, as well as metabolic changes. Browne et al. (1977) studied metabolic and experimental factors in the behavioral response to repeated amphetamine, highlighting the role of dosing regimens and individual differences. These adaptations are relevant to understanding the development of substance use disorders and the long-term effects of stimulant medications.
Clinical and Psychiatric Contexts
In simple terms: Amphetamine responses can differ in people with psychiatric conditions, such as borderline personality disorder.
Schulz et al. (1985) examined amphetamine response in borderline patients and found differences compared to controls, suggesting that psychiatric conditions can alter response to amphetamine. This underscores the importance of considering clinical heterogeneity when studying GO:0001975. Additionally, Elliott et al. (2020) conducted a systematic review and network meta-analysis of pharmacologic treatment of ADHD in adults, which includes amphetamine-based medications, demonstrating the clinical relevance of understanding amphetamine response.
Key Genes Involved in GO:0001975 response to amphetamine
The following genes have been implicated in the response to amphetamine based on human and preclinical studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC6A2 | Norepinephrine transporter; regulates synaptic norepinephrine | Genetic variation modulates acute subjective and cardiovascular response to d-amphetamine |
| DRD2 | Dopamine receptor D2; mediates dopamine signaling | Potential target for amphetamine effects on reward and locomotion |
| DRD4 | Dopamine receptor D4; involved in dopamine signaling | Associated with novelty seeking and response to stimulants |
| COMT | Catechol-O-methyltransferase; degrades dopamine and norepinephrine | Affects dopamine availability and amphetamine response |
| SLC6A3 | Dopamine transporter; regulates synaptic dopamine | Primary target of amphetamine for dopamine release |
| SLC6A4 | Serotonin transporter; regulates synaptic serotonin | Modulates amphetamine effects on mood and anxiety |
| MAOA | Monoamine oxidase A; degrades serotonin and norepinephrine | Influences monoamine levels and amphetamine sensitivity |
| MAOB | Monoamine oxidase B; degrades dopamine | Affects dopamine metabolism and amphetamine response |
| DBH | Dopamine beta-hydroxylase; converts dopamine to norepinephrine | Impacts norepinephrine synthesis and amphetamine effects |
| ADRA2A | Alpha-2A adrenergic receptor; regulates norepinephrine release | Modulates cardiovascular and subjective responses |
| ADRB1 | Beta-1 adrenergic receptor; mediates sympathetic effects | Involved in cardiovascular response to amphetamine |
| ADRB2 | Beta-2 adrenergic receptor; mediates sympathetic effects | Involved in cardiovascular and metabolic responses |
| HTR1B | Serotonin receptor 1B; modulates serotonin release | Associated with impulsivity and amphetamine response |
| BDNF | Brain-derived neurotrophic factor; supports neuronal plasticity | May mediate long-term adaptations to amphetamine |
| CREB1 | cAMP response element-binding protein; transcription factor | Regulates gene expression changes in response to amphetamine |
| FOS | Immediate early gene; marker of neuronal activation | Indicates brain regions activated by amphetamine |
| ARC | Activity-regulated cytoskeleton-associated protein | Involved in synaptic plasticity following amphetamine |
| TH | Tyrosine hydroxylase; rate-limiting enzyme in catecholamine synthesis | Affects dopamine and norepinephrine production |
How Is response to amphetamine Regulated?
The response to amphetamine is regulated at multiple levels, including genetic variation in monoamine transporters and receptors, epigenetic modifications, and environmental factors such as childhood adversity. For example, polymorphisms in SLC6A2 alter the acute response to d-amphetamine, and childhood adversity impacts subjective effects of stimulants. Additionally, repeated amphetamine exposure can induce neuroadaptive changes in gene expression via transcription factors like CREB and immediate early genes such as FOS and ARC.
response to amphetamine and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC6A2 | ADHD, cardiovascular response | Knockout or point mutation in cell lines; human iPSC-derived neurons |
| DRD2 | Substance use disorders, schizophrenia | Knockout mice; overexpression in neuronal cultures |
| COMT | Cognitive function, pain sensitivity | Point mutation knock-in mice; human cell lines |
| BDNF | Depression, addiction | Conditional knockout mice; neuronal cultures |
| CREB1 | Addiction, memory | Knockout or overexpression in cell lines; transgenic mice |
Attention Deficit Hyperactivity Disorder (ADHD)
Amphetamine-based medications are effective for ADHD, and individual variability in response to amphetamine can affect treatment outcomes. Elliott et al. (2020) conducted a network meta-analysis of pharmacologic treatments for adult ADHD, highlighting the importance of understanding amphetamine response for optimizing therapy.
Substance Use Disorders
Amphetamine is a drug of abuse, and the response to amphetamine is relevant to addiction liability. Neural responses to rewards, as studied by Melrose et al. (2016), may contribute to addictive behaviors. Genetic and environmental factors that modulate amphetamine response could influence vulnerability to substance use disorders [7,8].
Psychiatric Conditions
Altered amphetamine response has been observed in borderline personality disorder, suggesting that psychiatric conditions can affect drug response. Understanding these differences may inform personalized treatment approaches.
From response to amphetamine-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SLC6A2 variant alter amphetamine response? | Point mutation knock-in cell lines or human iPSC-derived neurons |
| What is the role of DRD2 in amphetamine reward? | DRD2 knockout mice or CRISPR knockout in neuronal cell lines |
| How does amphetamine affect gene expression? | RNA-seq in wild-type vs. knockout cells after amphetamine treatment |
| Can we visualize amphetamine-induced neural activation? | FOS-tagged knock-in reporter mice or immunostaining |
| Does overexpression of COMT alter amphetamine sensitivity? | COMT overexpression in cell lines or transgenic mice |
| What are the long-term adaptations to repeated amphetamine? | Repeated treatment in knockout/knock-in models followed by behavioral and molecular assays |
How to Study the response to amphetamine Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Subjective effect questionnaires | Self-reported mood, euphoria, energy | Human clinical pharmacology studies [2,3,7,8] |
| Cardiovascular monitoring | Heart rate, blood pressure | Human studies assessing physiological response [3,8] |
| fMRI | Brain activity in response to stimuli | Neuroimaging of reward processing |
| Locomotor activity | Behavioral activation | Rodent models of amphetamine sensitization |
| RNA-seq | Gene expression changes | Molecular response to amphetamine in cells or animal models |
| CRISPR knockout/knock-in | Causal role of specific genes | Cell lines or animal models to test candidate genes |
| Genotyping | Genetic variants associated with response | Human studies to identify pharmacogenetic markers |
Human Clinical Pharmacology Studies
Controlled human studies administer d-amphetamine and measure subjective effects, cardiovascular parameters, and cognitive performance. These studies often genotype participants for candidate genes such as SLC6A2 to assess genetic moderation [2,3,7,8].
Neuroimaging
Functional magnetic resonance imaging (fMRI) can measure neural responses to rewards or cognitive tasks after amphetamine administration. Melrose et al. (2016) used fMRI to show altered neural response to sucrose in healthy women.
Preclinical Behavioral and Metabolic Assays
Rodent models are used to study behavioral sensitization, locomotor activity, and metabolic changes following repeated amphetamine exposure. Browne et al. (1977) examined metabolic and experimental factors in the behavioral response to repeated amphetamine.
Molecular and Genetic Approaches
CRISPR-based gene editing, RNA interference, and overexpression systems in cell lines or animal models can elucidate the roles of specific genes in amphetamine response. These methods allow for causal testing of candidate genes identified in human studies.
How CRISPR Can Be Used to Study GO:0001975 response to amphetamine
Knockout
CRISPR knockout of candidate genes such as SLC6A2 or DRD2 in cell lines or animal models can determine their necessity for amphetamine response. For example, knocking out SLC6A2 in human iPSC-derived neurons could test its role in amphetamine-induced norepinephrine release.
Point Mutation
Introducing specific point mutations identified in human studies (e.g., SLC6A2 variants) into cell lines or animal models allows for functional validation of genetic associations with amphetamine response.
Knock-in
Knock-in of reporter genes such as FOS or ARC can enable visualization of neuronal activation following amphetamine exposure in vivo or in vitro.
Overexpression
Overexpression of genes like COMT or BDNF in cell lines or transgenic animals can test whether increased gene dosage alters amphetamine sensitivity and downstream signaling.
How EDITGENE Supports response to amphetamine Research
Researchers studying response to amphetamine-related genes often need to determine whether a candidate gene is causally involved in mediating the effects of amphetamine. EDITGENE provides a comprehensive suite of CRISPR-based services to facilitate this research, from gene knockout to precise point mutations and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for response to amphetamine research.
Frequently Asked Questions About response to amphetamine
What is GO:0001975 response to amphetamine?
GO:0001975 is a Gene Ontology biological process term that describes any change in a cell or organism's state or activity as a result of an amphetamine stimulus, including movement, secretion, enzyme production, and gene expression [QuickGO definition].
What genes are involved in response to amphetamine?
Genes such as SLC6A2, DRD2, DRD4, COMT, and BDNF have been implicated in modulating response to amphetamine [3,5].
How does SLC6A2 affect amphetamine response?
Variation in the norepinephrine transporter gene SLC6A2 modulates acute subjective and cardiovascular responses to d-amphetamine in healthy volunteers.
Does childhood adversity influence amphetamine response?
Yes, childhood adversity impacts acute subjective effects of stimulants, including amphetamine, as shown in placebo-controlled studies.
Are there ethnic differences in amphetamine response?
Asians compared to Whites show increased response to d-amphetamine on select subjective and cardiovascular measures.
What brain regions are involved in amphetamine response?
Amphetamine alters neural responses to rewarding stimuli such as sucrose, as measured by fMRI in healthy women.
How is amphetamine response studied in the lab?
Researchers use human clinical pharmacology studies, neuroimaging, preclinical behavioral assays, and molecular techniques such as CRISPR gene editing [2,3,5,6].
What is the role of dopamine in amphetamine response?
Amphetamine primarily acts by increasing dopamine release, and genes like DRD2 and SLC6A3 are key mediators of this response.
Can CRISPR be used to study amphetamine response?
Yes, CRISPR knockout, knock-in, and overexpression models can test the causal role of specific genes in amphetamine response.
What diseases are associated with altered amphetamine response?
ADHD, substance use disorders, and psychiatric conditions like borderline personality disorder have been linked to differences in amphetamine response [1,4].
Conclusion
GO:0001975 response to amphetamine is a critical biological process that encompasses the diverse physiological and behavioral changes induced by amphetamines. Research has identified key genetic and environmental factors that modulate this response, with implications for ADHD treatment, substance use disorders, and personalized medicine [1,2,3,7,8]. Continued investigation using advanced CRISPR models and multi-omics approaches will further elucidate the mechanisms underlying individual variability in amphetamine response.
References
- 1. Elliott J et al.. 2020. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.. PLoS One 15(10):e0240584 PMID: 33085721
- 2. Weafer J et al.. 2013. Inattention, impulsive action, and subjective response to D-amphetamine.. Drug Alcohol Depend 133(1):127-33 PMID: 23790566
- 3. Dlugos A et al.. 2007. Norepinephrine transporter gene variation modulates acute response to D-amphetamine.. Biol Psychiatry 61(11):1296-305 PMID: 17239355
- 4. Schulz SC et al.. 1985. Amphetamine response in borderline patients.. Psychiatry Res 15(2):97-108 PMID: 3862151
- 5. Melrose AJ et al.. 2016. Amphetamine alters neural response to sucrose in healthy women.. Psychiatry Res Neuroimaging 252:19-25 PMID: 27179312
- 6. Browne RG et al.. 1977. Metabolic and experimental factors in the behavioral response to repeated amphetamine.. Pharmacol Biochem Behav 6(5):545-52 PMID: 561406
- 7. Carlyle M et al.. 2024. Impact of childhood adversity on acute subjective effects of stimulant and opioid drugs: Evidence from placebo-controlled studies in healthy volunteers.. J Psychopharmacol 38(11):986-997 PMID: 39118370
- 8. Pang RD et al.. 2016. Asians compared to Whites show increased response to d-amphetamine on select subjective and cardiovascular measures.. Pharmacol Biochem Behav 144:73-7 PMID: 26952590
